Market Overview

Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock

Related OMER
9 IPOs That Fell Flat On Wall Street
Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®

Shares of Omeros's (NASDAQ: OMER) traded up as much as 6 percent Thursday morning after the company's announcement of an NDA submission for its intraocular lens replacement surgery treatment OMS302.

The stock charged to a session high of $6.19 (up 15 percent) heading into the last hour of the morning session following comments from Wedbush analyst Liana Moussatos.

She anticipates a 90 percent probability of the FDA accepting the filing for review by late September of this year, with 10-15 percent potential upside in this instance.

Moussatos estimates an 80 percent probability of the NDA being approved by the FDA in mid-2014 with potential upside of 20-40 percent if the approval is made.

Citing peak annual sales for OMS302 of about $479 million and potential partnerships and pipeline progress during the remainder of 2013, Moussatos reiterated an Outperform rating and $18 price target on OMER.

Latest Ratings for OMER

Aug 2015Roth CapitalInitiates Coverage onBuy
Feb 2014McNicoll Lewis VlakMaintainsBuy
Apr 2013WBB SecuritiesMaintainsStrong Buy

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings Movers


Related Articles (OMER)

View Comments and Join the Discussion!

Get Benzinga's Newsletters